{"id":5707,"date":"2025-05-20T09:20:18","date_gmt":"2025-05-20T09:20:18","guid":{"rendered":"https:\/\/optimumdermatology.com\/b-dermatiko-lemfoma-oriakhs-zonhs\/"},"modified":"2025-10-16T14:09:45","modified_gmt":"2025-10-16T14:09:45","slug":"b-dermatiko-lemfoma-oriakhs-zonhs","status":"publish","type":"page","link":"https:\/\/optimumdermatology.com\/en\/b-dermatiko-lemfoma-oriakhs-zonhs\/","title":{"rendered":"Primary Cutaneous Marginal Zone B-cell Lymphoma (PCMZL)"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t\t

\n\t\t\t\tPrimary Cutaneous Marginal Zone B-cell Lymphoma (PCMZL)\t\t\t\t<\/h1>\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Definition<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Primary Cutaneous Marginal Zone B-cell Lymphoma (PCMZL) is the second most common form of primary cutaneous B-cell lymphomas. It is associated with non-Hodgkin lymphomas, specifically with the extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT type).
Primary cutaneous B-cell lymphomas account for approximately 20\u201325% of all cutaneous lymphomas and generally present with an indolent clinical course, slow progression, and absence of severe symptoms.
\u2022 Specialized diagnosis
\u2022 Accurate imaging and staging
\u2022 Personalized therapeutic approach
\u2022 Progressive management
\u2022 Regular follow-up to prevent complications<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Symptoms<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

This type of lymphoma can manifest on any area of the skin, but it typically appears on the arms, legs, or trunk. The clinical presentation includes papules, nodules, or\u2014more rarely\u2014tumors.
In some cases, patients may show signs of infection with\u00a0Borrelia burgdorferi<\/em>, the bacterium associated with Lyme disease.
Characteristic lesions appear as erythematous to violaceous papules, plaques, or nodules, mainly on the upper limbs or trunk, and may recur over time.
Borrelia burgdorferi is considered a potential contributing factor. Extracutaneous spread or spontaneous regression is rare.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Diagnosis & Treatment<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The average age of onset is approximately 63 years. Clinical presentation may be atypical, such as cystic masses or pseudodermatitis, making diagnosis more challenging.
For solitary lesions, surgical excision or radiotherapy is typically recommended.
In more widespread or multifocal presentations, Rituximab is often the treatment of choice.
Due to the benign nature and favorable prognosis of PCMZL, a “watch-and-wait” strategy is often employed as first-line management.
However, proper staging using imaging methods such as computed tomography (CT) is essential to rule out systemic dissemination and secondary skin infiltration.
Overall, diagnosis and treatment require expert dermatologic evaluation and careful case-by-case management.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Primary Cutaneous Marginal Zone B-cell Lymphoma (PCMZL) Definition Primary Cutaneous Marginal Zone B-cell Lymphoma (PCMZL) is the second most common form of primary cutaneous B-cell lymphomas. It is associated with non-Hodgkin lymphomas, specifically with the extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT type).Primary cutaneous B-cell lymphomas account for approximately 20\u201325% of all cutaneous […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"tpl-side-nav.php","meta":{"footnotes":""},"class_list":["post-5707","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/optimumdermatology.com\/en\/wp-json\/wp\/v2\/pages\/5707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/optimumdermatology.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/optimumdermatology.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/optimumdermatology.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/optimumdermatology.com\/en\/wp-json\/wp\/v2\/comments?post=5707"}],"version-history":[{"count":4,"href":"https:\/\/optimumdermatology.com\/en\/wp-json\/wp\/v2\/pages\/5707\/revisions"}],"predecessor-version":[{"id":5711,"href":"https:\/\/optimumdermatology.com\/en\/wp-json\/wp\/v2\/pages\/5707\/revisions\/5711"}],"wp:attachment":[{"href":"https:\/\/optimumdermatology.com\/en\/wp-json\/wp\/v2\/media?parent=5707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}